Shenzhen Langbo Biopharmaceutical

Shenzhen Langbo Biopharmaceutical is a clinical-stage biotechnology company headquartered in Shenzhen, China, specializing in the development of innovative small molecule drugs for oncology. The company's primary focus is on the inhibition of protein phosphatase 2A (PP2A), a key regulator of cell signaling and DNA repair mechanisms. Its lead clinical candidate, LB-100, is being evaluated in multiple Phase 1 and Phase 2 trials, often in combination with standard-of-care therapies like chemotherapy and immunotherapy, to treat various solid tumors and hematological malignancies. Langbo Biopharmaceutical leverages its expertise in phosphatase biology to create a pipeline of first-in-class therapies aimed at overcoming drug resistance in cancer.